High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V

Molecular Oncology

Volumn 4, Issue 4, 2010, Pages 335-346

  Fritsche Polanz, Robert ^a,b   Fritz, Marika ^a   Huber, Andrea ^a   Sotlar, Karl ^c   Sperr, Wolfgang R ^a   Mannhalter, Christine ^a   Födinger, Manuela ^a,b   Valent, Peter ^a,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Institute of Laboratory Diagnostics   (Austria)

^c UNIVERSITY OF MUNICH   (Germany)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

AML; KIT D816V; Mastocytosis; Microdissection

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CELL; CHEMICAL ANALYSIS; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; KIT GENE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SYSTEMIC MASTOCYTOSIS;

EID: 77955275396     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2010.04.008     Document Type: Article

References (58)

1. Akin C., Brockow K., D'Ambrosio C., et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated forms of c-kit. Exp. Hematol. 2003, 31:686-692.
2. Akin C., Metcalfe D.D. Systemic mastocytosis. Annu. Rev. Med. 2004, 55:419-432.
3. Ashman L.K., Cambareri A.C., To L.B., Levinsky R.J., Juttner C.A. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Blood 1991, 78:30-37.
4. Ashman L.K., Ferrao P., Cole S.R., Cambareri A.C. Effects of mutant c-kit in early myeloid cells. Leuk. Lymphoma 2000, 37:233-243.
5. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann. Intern. Med. 1985, 103:620-625.
6. Bernd H.W., Sotlar K., Lorenzen J., et al. Acute myeloid leukaemia with t(8;21) associated with " occult" mastocytosis. Report of an unusual case and review of the literature. J. Clin. Pathol. 2004, 57:324-328.
7. Broudy V.C., Smith F.O., Lin N., Zsebo K.M., Egrie J., Bernstein I.D. Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. Blood 1992, 80:60-67.
8. Brunning R.D., Vardiman J., Matutes E., et al. Acute myeloid leukemia. World Health Organization (WHO) classification of tumours. Tumours of Haematopoietic and Lymphoid Tissues 2001, 77-105. IARC Press, Lyon. first ed. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
9. Bühring H.J., Ullrich A., Schaudt K., Muller C.A., Busch F.W. The product of the proto-oncogene c-kit (P145c-kit) is a human bone marrow surface antigen of hemopoietic precursor cells which is expressed on a subset of acute non-lymphoblastic leukemic cells. Leukemia 1991, 5:854-860.
10. Butterfield J.H., Weiler D., Dewald G., Gleich G.J. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk. Res. 1988, 12:345-355.
11. Cairoli R., Beghini A., Morello E., et al. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases. Leuk. Res. 2005, 29:397-400.
12. Cairoli R., Beghini A., Grillo G., et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006, 107:3463-3468.
13. Cammenga J., Horn S., Bergholz U., et al. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood 2005, 106:3958-3961.
14. Care R.S., Valk P.J., Goodeve A.C., et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br. J. Haematol. 2003, 121:775-777.
15. Escribano L., Orfao A., Diaz-Agustin B., et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998, 91:2731-2736.
16. Escribano L., Diaz-Agustin B., Lopez A., et al. Spanish Network on Mastocytosis (REMA). Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B. Clin. Cytom. 2004, 58:1-8.
17. Estey E., Döhner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
18. Feger F., Ribadeau Dumas A., Leriche L., Valent P., Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int. Arch. Allergy Immunol. 2002, 127:110-114.
19. Fritsche-Polanz R., Jordan J.H., Feix A., et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br. J. Haematol. 2001, 113:357-364.
20. Furitsu T., Tsujimura T., Tono T., et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J. Clin. Invest. 1993, 91:1736-1744.
21. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108:2366-2372.
22. Goemans B.F., Zwaan C.M., Miller M., et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005, 19:1536-1542.
23. Horny H.P., Ruck M., Wehrmann M., Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br. J. Haematol. 1990, 76:186-193.
24. Horny H.P., Sillaber C., Menke D., et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am. J. Surg. Pathol. 1998, 22:1132-1140.
25. Kirshenbaum A.S., Goff J.P., Kessler S.W., Mican J.M., Zsebo K.M., Metcalfe D.D. Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J. Immunol. 1992, 148:772-777.
26. Lawrence J.B., Friedman B.S., Travis W.D., Chinchilli V.M., Metcalfe D.D., Gralnic H.R. Hematologic manifestation of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am. J. Med. 1991, 91:612-624.
27. Longley B.J., Tyrrell L., Lu S.Z., et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 1996, 12:312-314.
28. Longley B.J., Metcalfe D.D., Tharp M., et al. Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis. Proc. Natl. Acad. Sci. (USA) 1999, 96:1609-1614.
29. Mayerhofer M., Gleixner K.V., Hoelbl A., et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J. Immunol. 2008, 180:5466-5476.
30. Metcalfe D.D. Classification and diagnosis of mastocytosis: current status. J. Invest. Dermatol. 1991, 96. 2S-4S.
31. Mrozek K., Heerema N.A., Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev. 2004, 18:115-136.
32. Nagata H., Worobec A.S., Oh C.K., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. (USA) 1995, 91:10560-10564.
33. Nanri T., Matsuno N., Kawakita T., et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia 2005, 19:1361-1366.
34. Schnittger S., Kohl T.M., Haferlach T., et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006, 107:1791-1799.
35. Schwartz L.B., Metcalfe D.D., Miller J.S., Earl H., Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N. Engl. J. Med. 1987, 316:1622-1626.
36. Schwartz L.B., Sakai K., Bradford T.R., et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J. Clin. Invest. 1995, 96:2702-2710.
37. Shimada A., Taki T., Tabuchi K., et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 2006, 107:1806-1809.
38. Sillaber C., Strobl H., Bevec D., et al. IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J. Immunol. 1991, 147:4224-4228.
39. Simmons P.J., Aylett G.W., Niutta S., To L.B., Juttner C.A., Ashman L.K. c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture. Exp. Hematol. 1994, 22:157-165.
40. Sotlar K., Marafioti T., Griesser H., et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol. Pathol. 2000, 53:188-193.
41. Sotlar K., Fridrich C., Mall A., et al. Detection of c-kit point mutation Asp-816 → Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk. Res. 2002, 26:979-984.
42. Sotlar K., Escribano L., Landt O., et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am. J. Pathol. 2003, 162:737-746.
43. Sperr W.R., Walchshofer S., Horny H.P., et al. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Br. J. Haematol. 1998, 103:740-749.
44. Sperr W.R., Horny H.P., Lechner K., Valent P. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk. Lymphoma 2000, 37:473-486.
45. Sperr W.R., Jordan J.H., Baghestanian M., et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001, 98:2200-2209.
46. Sperr W.R., Escribano L., Jordan J.H., et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk. Res. 2001, 25:529-536.
47. Sperr W.R., Horny H.P., Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int. Arch. Allergy Immunol. 2002, 127:140-142.
48. Stirewalt D.L., Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer 2003, 3:650-665.
49. Travis W.D., Li C.Y., Yam L.T., Bergstralh E.J., Swee R.G. Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988, 62:965-972.
50. Tsai M., Shih L.S., Newlands G.F., et al. The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo. Analysis by anatomical distribution, histochemistry, and protease phenotype. J. Exp. Med. 1991, 174:125-131.
51. Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk. Res. 2001, 25:603-625.
52. Valent P., Horny H.P., Li C.Y., et al. Mastocytosis (Mast cell disease). World Health Organization (WHO) classification of tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues 2001, vol. 1:291-302. IARC Press, Lyon. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
53. Valent P., Akin C., Escribano L., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur. J. Clin. Invest. 2007, 37:435-453.
54. Valent P., Spanblöchl E., Sperr W.R., et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 1992, 80:2237-2245.
55. Valent P. The riddle of the mast cell: kit(CD117)-ligand as the missing link?. Immunol. Today 1994, 15:111-114.
56. Valent P. Biology, classification and treatment of human mastocytosis. Wien. Klin. Wochenschr. 1996, 108:385-397.
57. Valent P., Akin C., Sperr W.R., et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br. J. Haematol. 2003, 122:695-717.
58. Zsebo K.M., Wypych J., McNiece I.K., et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 1990, 63:195-201.